Chae Moon Hong1, Ji-Yeon Shin2, Byeong Il Kim3, Ho-Chun Song4, Joon-Kee Yoon5, Kyoung Sook Won6, Seong-Min Kim7, Ihn Ho Cho8, Shin Young Jeong1, Sang-Woo Lee1, Jaetae Lee9. 1. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, 41944, Daegu, Republic of Korea. 2. Department of Preventive Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. 3. Department of Nuclear Medicine, Korea Atomic Energy Research Institute, Seoul, Korea. 4. Department of Nuclear Medicine, School of Medicine, Chonnam National University Medical School, Gwangju, Korea. 5. Department of Nuclear Medicine & Molecular Imaging, Ajou University School of Medicine, Suwon, Korea. 6. Department of Nuclear Medicine, School of Medicine, Keimyung University, Daegu, Korea. 7. Department of Nuclear Medicine, School of Medicine, Chungnam National University, Daejeon, Korea. 8. Department of Nuclear Medicine, School of Medicine, Yeungnam University, Daegu, Korea. 9. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, 41944, Daegu, Republic of Korea. jaetae@knu.ac.kr.
Abstract
PURPOSE: The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. METHODS: We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000, and December 31, 2005, from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio were compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. RESULTS: A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2-19.6) years. A total of 183 secondary cancers, which included 162 solid and 21 hematologic cancers, occurred in 173 patients (5.6%). There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. CONCLUSION: We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.
PURPOSE: The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. METHODS: We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000, and December 31, 2005, from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio were compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. RESULTS: A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2-19.6) years. A total of 183 secondary cancers, which included 162 solid and 21 hematologic cancers, occurred in 173 patients (5.6%). There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. CONCLUSION: We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.
Authors: Anna M Sawka; Lehana Thabane; Luciana Parlea; Irada Ibrahim-Zada; Richard W Tsang; James D Brierley; Sharon Straus; Shereen Ezzat; David P Goldstein Journal: Thyroid Date: 2009-05 Impact factor: 6.568
Authors: Briseis A Kilfoy; Tongzhang Zheng; Theodore R Holford; Xuesong Han; Mary H Ward; Andreas Sjodin; Yaqun Zhang; Yana Bai; Cairong Zhu; Grace L Guo; Nathaniel Rothman; Yawei Zhang Journal: Cancer Causes Control Date: 2008-11-19 Impact factor: 2.506
Authors: Chi Yun Yu; Omar Saeed; Alyse S Goldberg; Shafaq Farooq; Rouhi Fazelzad; David P Goldstein; Richard W Tsang; James D Brierley; Shereen Ezzat; Lehana Thabane; Charlie H Goldsmith; Anna M Sawka Journal: Thyroid Date: 2018-11-27 Impact factor: 6.568
Authors: Remco J Molenaar; Surbhi Sidana; Tomas Radivoyevitch; Anjali S Advani; Aaron T Gerds; Hetty E Carraway; Dana Angelini; Matt Kalaycio; Aziz Nazha; David J Adelstein; Christian Nasr; Jaroslaw P Maciejewski; Navneet S Majhail; Mikkael A Sekeres; Sudipto Mukherjee Journal: J Clin Oncol Date: 2017-12-18 Impact factor: 50.717